key: cord-0754930-orqulgfr
authors: Yadav, Pragya D.; Sapkal, Gajanan N.; Abraham, Priya; Deshpande, Gururaj; Nyayanit, Dimpal A; Patil, Deepak Y.; Gupta, Nivedita; Sahay, Rima R.; Shete, Anita M.; Kumar, Sanjay; Panda, Samiran; Bhargava, Balram
title: Neutralization potential of Covishield vaccinated individuals sera against B.1.617.1
date: 2021-05-17
journal: bioRxiv
DOI: 10.1101/2021.05.12.443645
sha: 8ed111d66acc6b4e5d5dbf811f44313b1a94be1f
doc_id: 754930
cord_uid: orqulgfr

Covishield comprises the larger proportion in the vaccination program in India. Hence, it is of utmost importance to understand neutralizing capability of vaccine against the B.1.617.1 variant which is considered to responsible for surge of the cases in India. The neutralizing-antibody (NAb) titer against B.1.167.1 and prototype B.1 variant (D614G) was determined of the vaccine sera (4 weeks after second dose) of COVID-19 naïve subjects (n=43) and COVID-19 recovered subjects (n=18). The results demonstrated that sera of COVID-19 recovered subjects (n=18) who received two doses of Covishield have higher NAb response compared to the COVID-19 naive with a significant difference (p<0.0001) in NAb titer against B.1 and B.1.617.1 In-spite of reduction in the neutralizing titer against B.1.617.1 variant; Covishield vaccine-induced antibodies are likely to be protective to limit the severity and mortality of the disease in the vaccinated individuals.

Further, we also determined the IgG titer against S1-RBD and observed a nonsignificant difference between COVID-19 recovered cases administered with 2 dose of vaccine and COVID-19 naïve vaccinated subjects ( Figure 1D ). 

The study was approved by the Institutional Biosafety Committee and Institutional

Human Ethics Committee of ICMR-NIV, Pune, India under the project 'Propagation of new SARS-CoV-2 variant isolate and characterization in cell culture and animal model'.

PDY and PA contributed to study design, data analysis, interpretation and writing and critical review. GNS, GRD, DYP, RRS, AMS, DAN and SK contributed to data collection, interpretation, writing and critical review. NG, SP, and BB contributed to the critical review and finalization of the paper.

Authors do not have a conflict of interest among themselves. 

New SARS-CoV-2 variants-clinical, public health, and vaccine implications

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity

Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in

Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees

SARS CoV-2 variant B.1.617.1 is highly pathogenic in hamsters than B.1 variant

COVID-19 vaccination

Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2

Neutralization of B.1.1. 28 P2 variant with sera of natural SARS-CoV-2 infection and recipients of BBV152 vaccine

Figure 1: Neutralization of B.1.617.1 variant: Comparison of NAb titer between COVID-19 naïve cases (green, n=43) and COVID-19 recovered cases (red, n=18) administered with 2 doses of vaccine

A neutralization reduction factor of 1.94 was observed between the B.1 (D614G) and B.1.617.1 variant. A two-tailed pair-wise comparison was performed using the Wilcoxon matched-pairs signed-rank test with a p-value of 0.05. **** represent p-value <0.001 and **p value=0.0038,ns= non-significant p-value (D) A comparison of IgG antibodytiter against RBD protein between COVID-19 naïve cases (n=43) and COVID-19 recovered cases (n=18) administered with 2 doses of vaccine